跳至主要内容
临床试验/EUCTR2011-001515-31-GR
EUCTR2011-001515-31-GR进行中(未招募)不适用

EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM ININFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL ORCONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTERRANDOMISED PHASE III TRIAL - meropenem for the treatment of late onset neonatal sepsis

PENTA Foundation Onlus0 个研究点目标入组 550 人开始时间: 2011年12月7日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
550

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Informed consent form signed by the parents/carers
  • - Chronological age below 90 days inclusive
  • - Chronological age greater or equal to 72 hours of life at beginning of
  • - Clinical or confirmed sepsis
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 550
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Administration of any systemic antibiotic regimen for more than 24
  • hours prior to the administration of the study drug, unless the change is
  • driven by the lack of efficacy of the former regimen;
  • - Severe congenital malformations if the infant is not expected to
  • survive for more than 3 months;
  • - Other situations where the treating physician considers a different
  • antibiotic regimen necessary;
  • - Known intolerance or contraindication to study medication;
  • - Participation in any other clinical study of investigational drugs;
  • - Renal failure (as defined by Akcan-Arikan et al., 2007) and
  • requirement for haemofiltration or peritoneal dialysis;
  • - Confirmed sepsis with microorganisms known to be resistant to study

研究者

发起方
PENTA Foundation Onlus

相似试验

进行中(未招募)
不适用
Meropenem for the treatment of serious bacterial infections in neonates and infants below 90 days of age inclusive
EUCTR2011-001515-31-EEFONDAZIONE PENTA ONLUS550
进行中(未招募)
不适用
MEROPENEM FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS IN NEONATES AND YOUNG INFANTSSUSPECTED OR PROVEN LATE ONSET NEONATAL SEPSISMedDRA version: 14.1Level: PTClassification code 10053840Term: Bacterial sepsisSystem Organ Class: 10021881 - Infections and infestations
EUCTR2011-001515-31-ESPENTA Foundation Onlus550
进行中(未招募)
不适用
Meropenem fot the treatment of serious bacterial infections in neonates and young infantssuspected or proven late onset neonatal sepsisMedDRA version: 14.1Level: PTClassification code 10040049Term: Sepsis neonatalSystem Organ Class: 10021881 - Infections and infestations
EUCTR2011-001515-31-LTPENTA Foundation Onlus550
已完成
不适用
Efficacy and safety of meropenem (3g/day) in the treatment of severe/refractory respiratory infectionssevere/refractory respiratory infections
JPRN-UMIN000011835Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan50
已完成
2 期
Antibiotic regimens for treatment of resistant pneumoniaCondition 1: Pneumonia. Condition 2: Pneumonia. Condition 3: Pneumonia.Pneumonia due to Klebsiella pneumoniaePneumonia due to PseudomonasPneumonia due to other aerobic Gram-negative bacteria
IRCT201509213449N19Vice Chancellor for Research, Tehran University of Medical Sciences20